Low blood concentrations of 25-hydroxyvitamin D3 are associated with increased mortality, while some studies suggest improved cardiovascular outcomes with vitamin D3 supplementation in chronic kidney disease. However, the physiological effects of vitamin D3 on the cardiovascular system remain poorly understood making it difficult to determine whether vitamin D3 supplementation might provide cardiovascular benefit or even cause harm. Thus here we investigated the effects of chronic 1,25-dihydroxyvitamin D3 treatment on intracellular signaling in human coronary artery smooth muscle cells (HCASMCs) and found that 1,25-dihydroxyvitamin D3 significantly potentiated endothelin (ET-1) signaling. Specifically, 1,25-dihydroxyvitamin D3 (24-h pretreatment) caused a more than threefold enhancement in both ET-1-induced intracellular calcium mobilization and extracellular signal-regulated kinase (ERK) activation. This 1,25-dihydroxyvitamin D3-elicited signaling enhancement was not observed for either vasopressin or carbachol. With the use of endothelin receptor (ETR) isoform-selective antagonists, ETRA was found to be primarily responsible for the 1,25-dihydroxyvitamin D3-induced ET-1 responsiveness and yet ETRA mRNA expression and protein abundance were unaltered following 1,25-dihydroxyvitamin D3 treatment. While there was an increase in ETRB mRNA expression in response to 1,25-dihydroxyvitamin D3, the protein abundance of ETRB was again unchanged. Finally, ETRA/ETRB heterodimerization was not detected in HCASMCs in either the absence or presence of 1,25-dihydroxyvitamin D3. Together, these data show for the first time that 1,25-dihydroxyvitamin D3 enhances endothelin responsiveness in HCASMCs and that the effect is mediated through ETRA.